Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer
Metrics: PDF 1558 views | HTML 2762 views | ?
Xiangrong Cui1,2,3,*, Xuan Jing5,*, Qin Yi1,2,3, Chunlan Long1,2,3, Bin Tan1,2,3, Xin Li1,2,3, Xueni Chen1,2,3, Yue Huang1,2,3, Zhongping Xiang1,2,3, Jie Tian4 and Jing Zhu1,2,3
1Pediatric Research Institute, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China
2China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China
3Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
4Cardiovascular Department (Internal Medicine), Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
5Clinical laboratory, Shanxi Province people’s hospital, Shanxi 030000, Taiyuan, China
*These authors contributed equally to this work
Jing Zhu, email: [email protected]
Keywords: STAT3; overall survival; mutation; copy number alteration
Received: August 14, 2017 Accepted: November 16, 2017 Published: December 14, 2017
Accumulated studies have provided controversial evidences of prognostic value for signal transducer and activator of transcription proteins 3 (STAT3) in cancers. To address this inconsistency, we performed a systematic analysis to determine whether STAT3 can serve as a prognostic marker in human cancers. STAT3 expression was assessed using Oncomine analysis. cBioPortal, Kaplan-Meier Plotter, and Prognoscan were performed to identify the prognostic roles of STAT3 in human cancers. The copy number alteration, mutation, interactive analysis, and visualize the altered networks were performed by cBioPortal. We found that STAT3 was more frequently overexpressed in lung, ovarian, gastric, blood and brain cancers than their normal tissues and its expression might be negatively related with the prognosis. In addition, STAT3 mutation mainly occurred in uterine cancer and existed in a hotspot in SH2 domain. Those findings suggest that STAT3 might serve as a diagnostic and therapeutic target for certain types of cancer, such as lung, ovarian, gastric, blood and brain cancers. However, future research is required to validate our findings and thus promote the clinical utility of STAT3 in those cancers prognosis evaluation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.